4 unknown, 1 not yet recruiting, 1 recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 4, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Xiaorong Dong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets brain radiotherapy, Sacituzumab Tirumotecan (Sac-TMT) - Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Xiaorong Dong | 53 | 2026-08-30 | 2026-08-27 |
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC Pembrolizumab, Plinabulin plus Etoposide and Platinum - Small Cell Lung Cancer Extensive Stage | Phase 2 | Recruiting | Xiaorong Dong | 45 | 2024-03-07 | 2025-02-11 |
| Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel - Non-small Cell Lung Cancer | Phase 2 | Unknown | Xiaorong Dong | 45 | 2022-12-01 | 2023-02-22 |
| Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy Pembrolizumab Combined With Chemotherapy - Gut Microbiota, NSCLC | Phase 1 / Phase 2 | Unknown | Xiaorong Dong | 40 | 2020-04-01 | 2020-04-03 |
| Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With PD-1/L1 Inhibitor - NSCLC, Anlotinib | Phase 2 | Unknown | Xiaorong Dong | 33 | 2020-04-01 | 2020-03-18 |
| SRS Sequential Sindilimab in Brain Metastasis of NSLSC SRS sequential sintilimab - NSCLC Stage IV, Brain Metastases | Phase 2 | Unknown | Xiaorong Dong | 25 | 2019-11-01 | 2019-11-27 |
Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (1)
Bevacizumab (1) · Drug Therapy (1) · Etoposide (1) · NPI 2358 (1) · Platinum (1) · anlotinib (1) · pembrolizumab (1)
China (3)